Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
162.74
-10.85 (-6.25%)
5:30:09 PM EDT: $164.60 +1.86 (+1.14%)
Products, Expansion

Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population

Published: 03/16/2021 11:34 GMT
Moderna Inc (MRNA) - Moderna Announces First Participants Dosed in Phase 2/3 Study of Covid-19 Vaccine Candidate in Pediatric Population.
Moderna - Study Will Evaluate Safety, Tolerability & Effectiveness of Two Doses of Mrna-1273 in Pediatric Participants Given 28 Days Apart.
Moderna - Phase 2/3 Mrna-1273 Study Expected to Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months to Less Than 12 Years in U.S. & Canada.
Further Company Coverage: Mrnao ((reuters.
Briefs@thomsonreuters.
Com;)).